{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.1","upperLimit":"93.4","value":"89.4"},{"groupId":"OG001","lowerLimit":"69.2","upperLimit":"81.9","value":"75.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"description":"DCR is defined as the percentage of patients with best overall response of CR, PR, or stable disease (SD) measured by investigator assessment per RECIST 1.1.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Up to approximately 120 months","title":"Disease Control Rate (DCR) by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}